| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12:55 | New report identifies stigma as a structural barrier in rare disease | ||
| 12:55 | GenAI in healthcare: why privacy and literacy matter more than the tech | ||
| Do | Patient-centricity in rare disease: accelerating the path to treatment | ||
| Do | Novo Nordisk and Vivtex partner in deal worth up to $2.1bn | ||
| Do | AI-enabled, human-interpreted: the future of pharma marketing insights is precision intelligence | ||
| Do | It's time for an end to pharma exceptionalism | ||
| Mi | The race to explore and harness GenAI in healthcare | ||
| Mi | The 'jagged frontier', straight talk and why humans still matter | ||
| Mi | GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension | ||
| Di | Novo Nordisk to lower list price, or wholesale acquisition cost, for Wegovy and Ozempic | ||
| Di | Incyte Biosciences UK announces NICE approval for Opzelura for vitiligo | ||
| Mo | Copenhagen Airports A/S, SAS Cargo and World Courier to host FlyPharma 2026 | ||
| Mo | Gilead to acquire Arcellx in deal worth $7.8bn | ||
| 20.02. | PureTech's deupirfenidone gets FDA and EC Orphan Drug Designations for idiopathic pulmonary fibrosis | ||
| 20.02. | CGT Catapult establishes Technology Advisory Board led by chair Phil Vanek | ||
| 19.02. | Diabeloop's DBLG2 receives FDA and CE clearance for automated insulin delivery without meal input | ||
| 19.02. | Human Continuum appoints Omar Khalid Sial as Chief Scientific Officer | ||
| 18.02. | British Chambers of Commerce partners with Singapore to scale up UK imports | ||
| 18.02. | The PM Society launches Pharmony to support more effective pharma-agency collaboration | ||
| 18.02. | Communication breakdown | ||
| 17.02. | UCB's Kygevi receives positive CHMP opinion for thymidine kinase 2 deficiency | ||
| 17.02. | THX Pharma appoints Julien Veys as Deputy CEO | ||
| 17.02. | Medicine shortages strike again - can radio-frequency identification technology help? | ||
| 16.02. | Pandemic readiness is now a financial risk test - and the UK must treat it that way | ||
| 16.02. | Study shows infants given RSV vaccination benefit beyond first RSV season |